Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 11/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7009871 | 0.94 | HPGD (0.44) | BDKRB1SLC6A3SLC6A4HPGDSMN1; SMN2 | |
| SCHEMBL31722799 | 0.89 | BDKRB1 (0.47) | BDKRB1HPGDSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2598198 | 0.89 | BDKRB1 (0.47) | BDKRB1HPGDSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL1271609 | 0.85 | MAPT (0.54) | HPGDSMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL3180920 | 0.85 | HPGD (0.47) | SLC6A3HPGDSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL6756374 | 0.83 | BDKRB1 (0.65) | BDKRB1SLC6A3SLC6A4ALDH1A1KDM4E | |
| SCHEMBL9196004 | 0.83 | BDKRB1 (0.42) | BDKRB1HPGDSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL20541747 | 0.82 | HPGD (0.45) | HPGDSMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL6850002 | 0.82 | ALDH1A1 (0.40) | BDKRB1HPGDSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL3974805 | 0.82 | HPGD (0.37) | BDKRB1HPGDSMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538133-B2 | Benzimidazole derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070259932-A1 | angiotensin II antagonists; Hypotensive agents; cardiovascular disorders; reacting Ethyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-mercaptobenzimidazole-7-carboxylic acid compound with alkylating agent | TAKEDA PHARMACEUTICAL COMPANY, LIMITED | 2007-11-08 | — | — | US | disclosed |
| US-7153972-B2 | Benzimidazole derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20050131039-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2005-06-16 | — | — | US | disclosed |
| US-6844443-B2 | Benzimidazole derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY, LTD. (JP) | 2005-01-18 | — | — | US | disclosed |
| US-20040044223-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2004-03-04 | — | — | US | disclosed |
| US-6608210-B2 | Such as 1-(cyclohexyloxycarbonyloxy)ethyl-2-ethoxy-1-((2'-(1H-tetrazol-t-yl)biphenyl-4-yl)methyl) benzimidazol-7-carboxylate; exhibits antihypertensive activity and strong angiotensin II antagonistic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-0720982-B1 | Benzimidazole derivatives, their production and use and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-11-13 | — | — | EP | disclosed |
| US-20020151723-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2002-10-17 | — | — | US | disclosed |
| US-6355808-B2 | ANGAGONIZING ANGIOTENSIN II | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| US-20010047020-A1 | Benzimidazole derivatives, their production and use | TAKEDA PHARAMCEUTICAL COMPANY, LIMITED (JP) | 2001-11-29 | — | — | US | disclosed |
| US-6232334-B1 | HAVE POTENT ANGIOTENSIN II ANTAGONISTIC ACTIVITY AND ANTIHYPERTENSIVE ACTIVITY, FOR TREATING CIRCULATORY SYSTEM DISEASES SUCH AS HYPERTENSIVE DISEASES, HEART DISEASES, STROKES, CEREBRAL APOPLEXY AND NEPHRITIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-15 | — | — | US | disclosed |
| US-6004989-A | ETHYL 2-ETHOXY-1-(2'-1H-TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL) BENZIMIDAZOLE-7-CARBOXYLATE AND SALTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-21 | — | — | US | disclosed |
| US-5962491-A | ANGIOTENSIN ANTAGONIST, HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS, STROKES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5705517-A | ANGIOTENSIN II ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-01-06 | — | — | US | disclosed |
| US-5703110-A | HYPOTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-12-30 | — | — | US | disclosed |
| EP-0720982-A1 | Benzimidazole derivatives, their production and use and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-10 | — | — | EP | disclosed |
| EP-0459136-A1 | Benzimidazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259932-A1 | angiotensin II antagonists; Hypotensive agents; cardiovascular disorders; reacting Ethyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-mercaptobenzimidazole-7-carboxylic acid compound with alkylating agent | AGTR1, REN, AGTR2 | BDKRB1 404/4885SLC6A3 2488/4885SLC6A4 2693/4885 |
| US-20050131039-A1 | Benzimidazole derivatives, their production and use | MRM1, CARM1, H1-4 | BDKRB1 1089/4885SLC6A3 4165/4885SLC6A4 2764/4885 |
| US-20040044223-A1 | Benzimidazole derivatives, their production and use | HAT1, MRM1, H1-4 | BDKRB1 1666/4885SLC6A3 4217/4885SLC6A4 2518/4885 |
| US-20020151723-A1 | Benzimidazole derivatives, their production and use | HAT1, MRM1, NSD1 | BDKRB1 1539/4885SLC6A3 3927/4885SLC6A4 2100/4885 |
| US-20010047020-A1 | Benzimidazole derivatives, their production and use | REN, AGTR1, H1-3 | BDKRB1 280/4885SLC6A3 4031/4885SLC6A4 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.